Experimental Allergic Encephalomyelitis (EAE)-Related Peptides Products

 Experimental Allergic Encephalomyelitis (EAE) Peptides are active fragment of the myelin basic protein. By a cellmediated immune response, the peptide causes experimental allergic encephalomyelitis, which is an inflammatory demyelinating disease of the central nervous system. These peptides have been used as a model for studying multiple sclerosis (MS) due to the clinical and histopathological similarities of the inflammatory diseases affecting the central nervous system. Both Myelin PLP (PLP-3602-PI) and MOG (PMG-3660-PI) are antigenic peptides that induce EAE by binding to MHCII molecules on antigen presenting cells where they are recognized by class-II restricted T cells.

Discovery
Westall et al., in 1971 identified a peptide that causes experimental allergic encephalomyelitis ^1,2. EAE is an autoimmune disease inducible by encephalitogenic helper T cells expressing Vβ8. Owhashi M et al., in 1997 examined the relationship between the stressor-induced alternation of clinical EAE and the induction of autoreactive T cells using Lewis rats ³.

Structural Characteristics
Belogurov AA et al demonstrated that autoantibodies (AAb) in multiple sclerosis (MS) reveal site-specific binding and cleavage toward myelin basic protein (MBP) epitope library. They have found several fragments of MBP immunodominant in terms of AAb binding and applied these peptides to DA rats with induced protracted relapsing EAE most closely related to MS. DA rats with EAE induced by syngenic spinal cord homogenate in complete Freund's adjuvant were treated by nasal route with human MBP 46–62, 81–102, 124–139, 147–170, and Copaxone®. MBP 124–139 and 147–170 displayed only mild therapeutic effects but MBP 46–62 significantly reduced EAE, reflected by lower clinical scores and shorter EAE duration compared to controls ⁴.  Three peptides overlapping the tryptophan region of bovine CNS myelin basic protein were synthesized by the solid phase procedure of Merrifield. These were the nonapeptide H-Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys-OH, the octapeptide H-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys-OH, and the heptapeptide H-Trp-Gly-Ala-Glu-Gly-Gln-Lys-OH. They were tested fro encephalitogenic activity in guinea pigs with either Freund's complete adjuvant containing M. tuberculosis or muramyl dipeptide in incomplete Freud's adjuvant at doses of 10 µg per animal. The results show that deletion of one or two residues from the amino-terminal end of the nonapeptide destroyed the ability of the shorter peptides to induce clinical but not histological signs of EAE ⁵. 

Mode of Action
Proteolipid protein (PLP) is the major protein of central nervous system (CNS) myelin. SJL(H-2S) mice immunized with a synthetic peptide corresponding to PLP residues 139-151 (HSLGKWLGHPDKF) develop acute EAE. A T cell line and 4 clones were derived from SJL/J mice were immunizied with this synthetic peptide. Severe clinical and histological EAE was induced by adoptive transfer of the peptide-specific T cell line and 3 of 4 T cell clones. The T cell line/clones all responded strongly to PLP peptide 139-151 in in vitro proliferative assays. However, two different reactivity patterns emerged when truncated PLP peptides 141-150 and 141-149 were tested, suggesting that more than 1 epitope may be present within the PLP 139-151 determinant. Two truncated PLP peptides were compared for the ability to induce EAE in vivo and proliferative responses in vitro. Immunization with PLP peptide 141-150 induced acute EAE in about 70% of mice tested, but PLP peptide 141-149 induced a comparatively mild form of EAE in 4 out of 9 mice tested. Lymph node cells from mice immunized with these peptides showed in vitro proliferative responses to each of the peptides, but the response to peptide 139-151 was always strongest. These combined in vivo and in vitro data further define the epitopes involved in PLP-induced EAE in SJL mice. Furthermore, the availability of multiple PLP-specific T cell clones will enable to study the diversity of the T cell repertoire to PLP ⁶.

Functions
Cell mediated autoimmune response, EAE is a cell mediated autoimmune response directed against autologous central nervous system myelin ⁷.
Sensitization with myelin basic protein (MBP), a major protein constituent of central nervous system compact myelin, emulsified in complete Freund's adjuvant, produce the full clinical and histological picture of EAE in a wide variety of animal.
The encephalitogenic determinants responsible for EAE induction are species-specific. That is, different sequences of amino acid residues located at unique positions within the MBP molecule are critical for the induction of EAE in each mammalian species ⁸.
Stressor-induced suppression of clinical EAE is not simply because of the failure of induction of autoreactive T cells, nor localization of the autoreactive T cells in the central nervous system ³.
Species-specific immune response, the capacity of MBP in complete Freund's adjuvant to induce an encephalitogenic immune response against autologous central nervous system myelin in a given mammalian species appears to be dictated by latent, species-specific immune response genes which presumably encode antigen-receptor molecules recognizing specific MBP sequences ¹.

References

1. Westall FC, Robinson AB, Caccam J, Jackson J, Ylar EH, (1971). Essential chemical requirements for induction of allergic encephalomyelitis. Nature, 229(5279):22-24.
2. Shapira R, Chou FC, McKneally S, Urban E, Kibler RF (1971). Biologicl activity and synthesis of an encephalitogenic determinant. Science, 173(998):736-738.
3. Owhashi M, Shouzui Y, Arita H (1997). Stress down-regulates experimental allergic encephalomyelitis (EAE) but permits activation and localization of autoreactive vβ8.2+ T Cells.  International Journal of Neuroscience, 89(3-4):177-188.
4. Belogurov AA Jr, Zargarova TA, Turobov VI, Novikova NI, Favorova OO, Ponomarenko NA, Gabibov AG  (2009). Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46–62.   Autoimmunity, 42(4):362-364.
5. Levit S, Powers JM, Milek D, Brostoff SW (1980). Peptide length requirement for experimental allergic encephalomyelitis in guinea pigs. Neurochem Res., 5(1):37-42.
6.  Kuchroo VK, Sobel RA, Yamamura T, Greenfield E, Dorf ME, Lees MB (1991). Induction of Experimental Allergic Encephalomyelitis by Myelin Proteolipid-Protein-Specific T Cell Clones and Synthetic Peptides. Pathobiology, 59(5):305-312.

7. Paterson PY (1982). Molecular and cellular determinants of neuroimmunologic inflammatory disease. Fed. Proc. Fed. Am. Soc. Exp. Biol., 41:2569-2576.
8. Hashim GA (1978). Myelin basic protein: structure, function and antigenic determinants. Immunol. Rev., 39:60-107.